NCT06123468 - Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 17, 2024

Primary Completion Date

February 28, 2027

Study Completion Date

March 31, 2027

Conditions

Esophagogastric Adenocarcinoma

Interventions

DRUG

Sacituzumab govitecan

10 mg/kg i.v. at day 1 and day 8 of each 21-day cycle (Q3W) for max 17 cycles (max. 12 months treatment)

Trial Locations (8)

SCRI-CCCIT GmbH, Salzburg

Hämatologisch-Onkologische Praxis Eppendorf, Hamburg

Universitätsklinikum Mannheim, Mannheim

Nationales Centrum für Tumorerkrankungen, Heidelberg

Klinikum rechts der Isar der TU München, München

Universitätsklinikum Jena, Jena

Universitätsklinikum Leipzig, Leipzig

Onkopraxis Probstheida, Leipzig